JingJing Li

Title: Innovations in Cancer Immunotherapy by JingJing Li

Introduction

JingJing Li is an accomplished inventor based in Chapel Hill, NC (US). He has made significant contributions to the field of cancer immunotherapy through his innovative research and development of chimeric antigen receptors.

Latest Patents

JingJing Li holds a patent for "Highly modular biepitopic and bispecific CAR-T cells for cancer immunotherapy." This patent describes biepitopic or bispecific chimeric antigen receptors that utilize a combination of single domain antibody mimics. These mimics can be monobodies, affibodies, or DARPins. The chimeric antigen receptors are designed to recognize two different epitopes of the same tumor antigen, such as HER-2 or EGFR. Additionally, they may recognize two epitopes from different tumor antigens, enhancing their effectiveness in cancer treatment. The application of these chimeric antigen receptors in immune cells represents a promising advancement in cancer immunotherapy.

Career Highlights

JingJing Li is affiliated with the University of North Carolina at Chapel Hill, where he continues to advance his research in immunotherapy. His work has garnered attention for its potential to improve cancer treatment outcomes.

Collaborations

JingJing Li collaborates with notable colleagues, including Rihe Liu and Gianpietro Dotti, to further enhance the impact of his research in the field of cancer immunotherapy.

Conclusion

JingJing Li's innovative work in developing advanced chimeric antigen receptors showcases his commitment to improving cancer treatment through cutting-edge research. His contributions are paving the way for new therapeutic strategies in immunotherapy.